Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Psychopharmacology [[electronic resource] ] : an introduction / / René Spiegel ; with contributions by S. Hossein Fatemi ... [et al.]
| Psychopharmacology [[electronic resource] ] : an introduction / / René Spiegel ; with contributions by S. Hossein Fatemi ... [et al.] |
| Autore | Spiegel René |
| Edizione | [4th ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 |
| Descrizione fisica | 1 online resource (424 p.) |
| Disciplina |
615.78
615/.78 |
| Altri autori (Persone) | FatemiS. Hossein |
| Soggetto topico | Psychopharmacology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
9786610101603
0-470-86947-X 1-280-10160-1 0-470-86946-1 0-470-34553-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Psychopharmacology; Contents; Preface; Preface to Third Edition; Preface to Second Edition; Foreword (by Herbert Meltzer); 1 Modern Psychopharmaceuticals (Revision by Hossein Fatemi); 1.1 Definition and classification; 1.2 Antipsychotics; 1.2.1 Clinical actions and uses; 1.2.2 The best-known products; 1.2.3 Differences between different products; 1.2.4 Side effects ('adverse effects') of antipsychotics; 1.2.5 Neuroleptics and tardive dyskinesias: unanswered questions; 1.3 Antidepressants; 1.3.1 Clinical actions and uses; 1.3.2 The best-known products; 1.3.3 How effective are antidepressants?
1.3.4 Side effects of antidepressants1.4 Mood stabilizers; 1.4.1 Clinical actions and uses; 1.4.2 Side effects of mood stabilizers; 1.5 Anxiolytics and hypnotics; 1.5.1 Clinical actions and uses; 1.5.2 The best-known products; 1.5.3 Anxiolytics or psychotherapy?; 1.5.4 Side effects of anxiolytics; 1.5.5 Dependency on benzodiazepines; 1.5.6 Alternatives to benzodiazepines; 1.6 Psychostimulants; 1.6.1 Actions and uses of psychostimulants; 1.6.2 The best-known psychostimulants; 1.7 Nootropics and antidementia drugs; 1.8 Concluding comment; 2 The History of Psychopharmacology; 2.1 Introduction 2.2 Psychopharmacology in the ancient world and Middle Ages2.2.1 The most important substances; 2.2.2 Psychopharmaceuticals and the history of psychiatry; 2.3 The modern age: psychopharmacology before chlorpromazine; 2.4 The discovery of modern psychopharmaceuticals; 2.4.1 Chlorpromazine; 2.4.2 Antidepressants; 2.4.3 Tranquillizers; 2.5 Discussion: how were modern psychopharmaceuticals discovered?; 2.5.1 Chance discovery; 2.5.2 Serendipity and spirit of the age (Zeitgeist); 2.5.3 Quantitative aspects; 2.6 The past 20 years; 2.6.1 Atypical antipsychotic drugs; 2.6.2 New antidepressants: SSRIs 2.6.3 Drugs to treat Alzheimer's disease (AD)2.7 Concluding remarks; 3 Effects of Psychotropic Medication on Healthy Subjects; 3.1 Introduction; 3.2 Studies conducted by Emil Kraepelin; 3.3 Assessment methods used in drug experiments on healthy volunteers; 3.3.1 Methods for recording subjective drug effects; 3.3.2 Methods for recording behavioral drug effects; 3.3.3 Neurophysiological parameters; 3.4 Findings in drug experiments on healthy volunteers; 3.4.1 Antipsychotic drugs; 3.4.2 Antidepressant drugs; 3.4.3 Anxiolytic and hypnotic drugs; 3.4.4 Psychostimulant drugs 3.4.5 Nootropics and antidementia drugs3.5 Discussion; 3.5.1 Differential drug effects; 3.5.2 Sensitivity of the assessment methods used in pharmacopsychology; 3.5.3 Understanding and predicting clinical drug effects; 3.5.4 Theory-orientated issues; 3.6 Conclusions; 4 Preclinical Research in Psychopharmacology (by Conrad Gentsch); 4.1 Introduction; 4.2 The target; 4.2.1 The nervous system; 4.2.2 Neurons; 4.2.3 Synapses; 4.2.4 Receptors; 4.2.5 Ligands; 4.2.6 Interaction between the ligand and receptor; 4.2.7 Neurotransmitters 4.3 Hypotheses relating to the mode of action of psychopharmaceuticals |
| Record Nr. | UNINA-9910144731203321 |
Spiegel René
|
||
| Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Psychopharmacology [[electronic resource] ] : an introduction / / René Spiegel ; with contributions by S. Hossein Fatemi ... [et al.]
| Psychopharmacology [[electronic resource] ] : an introduction / / René Spiegel ; with contributions by S. Hossein Fatemi ... [et al.] |
| Autore | Spiegel René |
| Edizione | [4th ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 |
| Descrizione fisica | 1 online resource (424 p.) |
| Disciplina |
615.78
615/.78 |
| Altri autori (Persone) | FatemiS. Hossein |
| Soggetto topico | Psychopharmacology |
| ISBN |
9786610101603
0-470-86947-X 1-280-10160-1 0-470-86946-1 0-470-34553-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Psychopharmacology; Contents; Preface; Preface to Third Edition; Preface to Second Edition; Foreword (by Herbert Meltzer); 1 Modern Psychopharmaceuticals (Revision by Hossein Fatemi); 1.1 Definition and classification; 1.2 Antipsychotics; 1.2.1 Clinical actions and uses; 1.2.2 The best-known products; 1.2.3 Differences between different products; 1.2.4 Side effects ('adverse effects') of antipsychotics; 1.2.5 Neuroleptics and tardive dyskinesias: unanswered questions; 1.3 Antidepressants; 1.3.1 Clinical actions and uses; 1.3.2 The best-known products; 1.3.3 How effective are antidepressants?
1.3.4 Side effects of antidepressants1.4 Mood stabilizers; 1.4.1 Clinical actions and uses; 1.4.2 Side effects of mood stabilizers; 1.5 Anxiolytics and hypnotics; 1.5.1 Clinical actions and uses; 1.5.2 The best-known products; 1.5.3 Anxiolytics or psychotherapy?; 1.5.4 Side effects of anxiolytics; 1.5.5 Dependency on benzodiazepines; 1.5.6 Alternatives to benzodiazepines; 1.6 Psychostimulants; 1.6.1 Actions and uses of psychostimulants; 1.6.2 The best-known psychostimulants; 1.7 Nootropics and antidementia drugs; 1.8 Concluding comment; 2 The History of Psychopharmacology; 2.1 Introduction 2.2 Psychopharmacology in the ancient world and Middle Ages2.2.1 The most important substances; 2.2.2 Psychopharmaceuticals and the history of psychiatry; 2.3 The modern age: psychopharmacology before chlorpromazine; 2.4 The discovery of modern psychopharmaceuticals; 2.4.1 Chlorpromazine; 2.4.2 Antidepressants; 2.4.3 Tranquillizers; 2.5 Discussion: how were modern psychopharmaceuticals discovered?; 2.5.1 Chance discovery; 2.5.2 Serendipity and spirit of the age (Zeitgeist); 2.5.3 Quantitative aspects; 2.6 The past 20 years; 2.6.1 Atypical antipsychotic drugs; 2.6.2 New antidepressants: SSRIs 2.6.3 Drugs to treat Alzheimer's disease (AD)2.7 Concluding remarks; 3 Effects of Psychotropic Medication on Healthy Subjects; 3.1 Introduction; 3.2 Studies conducted by Emil Kraepelin; 3.3 Assessment methods used in drug experiments on healthy volunteers; 3.3.1 Methods for recording subjective drug effects; 3.3.2 Methods for recording behavioral drug effects; 3.3.3 Neurophysiological parameters; 3.4 Findings in drug experiments on healthy volunteers; 3.4.1 Antipsychotic drugs; 3.4.2 Antidepressant drugs; 3.4.3 Anxiolytic and hypnotic drugs; 3.4.4 Psychostimulant drugs 3.4.5 Nootropics and antidementia drugs3.5 Discussion; 3.5.1 Differential drug effects; 3.5.2 Sensitivity of the assessment methods used in pharmacopsychology; 3.5.3 Understanding and predicting clinical drug effects; 3.5.4 Theory-orientated issues; 3.6 Conclusions; 4 Preclinical Research in Psychopharmacology (by Conrad Gentsch); 4.1 Introduction; 4.2 The target; 4.2.1 The nervous system; 4.2.2 Neurons; 4.2.3 Synapses; 4.2.4 Receptors; 4.2.5 Ligands; 4.2.6 Interaction between the ligand and receptor; 4.2.7 Neurotransmitters 4.3 Hypotheses relating to the mode of action of psychopharmaceuticals |
| Record Nr. | UNINA-9910830009303321 |
|
Spiegel René
|
||
| Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||